Healthcare resource utilization among haemophilia A patients in the United States

Haemophilia

Volumn 18, Issue 3, 2012, Pages 332-338

  Valentino, L A ^a   Pipe, S W ^b   Tarantino, M D ^c   Ye, X ^d   Xiong, Y ^e   Luo, M P ^d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Bleeding and Clotting Disorders Institute   (United States)

^d Baxter Bioscience   (United States)

^e BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Cost; Economics; Haemophilia; Inhibitors; Surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ARTICLE; CHILD; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE DISTRIBUTION; HEALTH CARE UTILIZATION; HEMOPHILIA A; HOSPITAL PATIENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTPATIENT DEPARTMENT; PHARMACY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; COAGULANTS; DATABASES, FACTUAL; FACTOR VIII; HEALTH CARE COSTS; HEALTH RESOURCES; HEMOPHILIA A; HUMANS; INFANT; INSURANCE, HEALTH; UNITED STATES; YOUNG ADULT;

EID: 84860335262     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02677.x     Document Type: Article

References (32)

1. Globe DR, Cunningham WE, Andersen R et al. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A. Haemophilia 2003; 9: 325-31.
2. Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10(Suppl 1): 63-70.
3. Fischer K, Van den Berg HM, Thomas R et al. Dose and outcome of care in haemophilia - how do we define cost-effectiveness? Haemophilia 2004; 10(Suppl 4): 216-20.
4. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
5. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9(Suppl 1): 19-26.
6. Srivastava A, Giangrande PL, Poon MC, Chua M, McGraw A, Wiedel J. Guidelines for the management of hemophilia. Montreal, QC: World Federation of Hemophilia, 2005.
7. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
8. Medical and Scientific Advisory Council. MASAC document #179. Recommendation Concerning Prophylaxis (Regular administration of clotting factor concentrate to prevent bleeding). 2007. Available at Accessed July 28, 2011.
9. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006; 12: 75-81.
10. Manco-Johnson M, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
11. Mejia-Carvajal C, Czapek EE, Valentino LA. Life expectancy in hemophilia outcome. J Thromb Haemost 2006; 4: 507-9.
12. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
13. Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 2006; 12: 579-90.
14. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
15. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
16. Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost 2004; 2: 861-2.
17. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
18. Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14(Suppl 6): 20-2.
19. Dimichele DM. Management of factor VIII inhibitors. Int J Hematol 2006; 83: 119-25.
20. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77(Suppl 1): 25-7.
21. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
22. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547-54.
23. Clinical Growth Charts. Centers for Disease Control and Prevention. 2000. Available at Accessed December 22, 2010.
24. Bureau of Labor Statistics. Consumer Price Indexes. Available at Accessed June, 2011.
25. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
26. Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia 2010; 16: 247-55.
27. Chang H, Sher GD, Blanchette VS, Teitel JM. The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia 1999; 5: 247-52.
28. Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors. Haemophilia 2006; 12(Suppl 6): 74-80.
29. Gautier P, D'Alche-Gautier MJ, Coatmelec B et al. Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors: experience of six French haemophilia centres. Haemophilia 2002; 8: 674-9.
30. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
31. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
32. Di Paola J, Aledort L, Britton H et al. Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia 2006; 12: 591-7.